People taking GLP-1 drugs have a low risk of hair loss, which is significantly higher than for those on other diabetes medications, a new study has found.

Absolute risk of alopecia was low, however

The study looked at 50,000 people on the drugs

The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type…

GLP-1 drugs such as Wegovy and Ozempic have been revolutionary for obesity and type 2 diabetes treatments, but questions remain about some of the side effects and potential…

Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged…

E' la conclusione di uno studio americano pubblicato su 'The Bmj': gli effetti collaterali di semaglutide e tirzepatide

People on GLP-1 agonist drugs such as Mounjaro, Ozempic and Wegovy have been reporting hair loss

Chi assume farmaci a base di semaglutide o tirzepatide per il trattamento del diabete e dell'obesità potrebbe dover prestare attenzione anche a un possibile effetto collaterale…

People taking GLP-1 drugs have a low risk of hair loss, which is significantly higher than for those on other diabetes medications, a new study has found.

Secondo un nuovo studio, chi assume farmaci GLP-1 ha un rischio basso di perdita dei capelli, ma comunque superiore rispetto a chi prende altri antidiabetici.

New research suggests that hair loss can be a real, if tiny, risk of starting a GLP-1 drug like Ozempic.